Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Total Current Liabilities (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Total Current Liabilities for 6 consecutive years, with $25.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 49.58% to $25.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $25.6 million, a 49.58% decrease, with the full-year FY2025 number at $25.6 million, down 49.58% from a year prior.
  • Total Current Liabilities was $25.6 million for Q4 2025 at Relay Therapeutics, down from $32.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $71.6 million in Q2 2023 to a low of $16.1 million in Q1 2021.
  • A 5-year average of $42.3 million and a median of $39.4 million in 2022 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 161.95% in 2022, then plummeted 52.49% in 2023.
  • Relay Therapeutics' Total Current Liabilities stood at $24.3 million in 2021, then surged by 161.95% to $63.7 million in 2022, then tumbled by 52.49% to $30.3 million in 2023, then surged by 67.59% to $50.7 million in 2024, then tumbled by 49.58% to $25.6 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Total Current Liabilities are $25.6 million (Q4 2025), $32.6 million (Q3 2025), and $32.5 million (Q2 2025).